Casper Medical is developing a magnesium fully resorbable scaffold designed to treat arterial stenosis in both coronary and peripheral arteries.
Engineered to provide effective temporary vessel support, Casper's MRS maintains radial strength during the critical healing period, then resorbs completely within a year, leaving the artery free to heal naturally.
Unlike permanent stents, Casper combines mechanical support with targeted Umirolimus therapy, delivering medication locally to reduce restenosis risk while minimizing long-term complications such as thrombosis.
Team
Jeff Jump
Board Chairman
Jeff has over 45 years’ experience in the international medical devices industry, 20 years of which have been at Board level. He was most recently Chairman and CEO of MedAlliance, a specialist in the development of treatments for coronary and peripheral artery disease, which he founded and was bought by Cordis for $1.2B. He was formerly CEO of SGX publicly listed company Biosensors, where he spent 13 years. During this time the company grew from a start-up to become the fourth largest supplier of cardiac drug eluting stents in the world. In addition to President and CEO he served as a Board Director of Biosensors. Jeff was founder and CEO of Xitact, which was bought by Mentice, a public company in Sweden.
Jeff has over 45 years’ experience in the international medical devices industry, 20 years of which have been at Board level. He was most recently Chairman and CEO of MedAlliance, a specialist in the development of treatments for coronary and peripheral artery disease, which he founded and was bought by Cordis for $1.2B. He was formerly CEO of SGX publicly listed company Biosensors, where he spent 13 years. During this time the company grew from a start-up to become the fourth largest supplier of cardiac drug eluting stents in the world. In addition to President and CEO he served as a Board Director of Biosensors. Jeff was founder and CEO of Xitact, which was bought by Mentice, a public company in Sweden. He has had key management positions at Haemonetics (part of the management buyout and eventual IPO on the NYSE), Shiley (bought by Pfizer), CTS (IPO and then bought by Guidant), and Embolx (bought by Edwards and Boston Scientific) Jeff has also been a Non-Executive Director of various medical device companies including Symetis (bought by Boston Scientific), PneumRx (Bought by BTG/Boston Scientific), Maya (sold to Covidien), and Veryan (sold to Osuka). He has also been Chairman of both Combioxin S.A. (Sold to Eagle Pharmaceuticals). Jeff is currently serving as a Chairman of Board for Casper Medical, TexRay, and Transluminal/Circlage and a board member of Valcare and Compahya SA.
Debashis Dutta, PhD
VP Engineering
Over 25 years of leadership experience in medical device research and development and product development. Vice President of Research and Development, Scientific Affairs and Quality at Biosensors International for 12 years. Senior research and development positions at Guidant and Avantec Vascular, which was acquired by Goodman Japan. Led hands-on development and transfer to manufacturing of several commercially successful drug-eluting stents, coronary and peripheral stents, and balloon catheters. Successfully led technical teams to obtain PMA approval for the first polymer-free drug-eluting stent in the United States. Holds 24 issued US medical device patents and has authored over 25 scientific publications.
Clinical Landscape
Current treatment options for coronary and peripheral artery disease face significant limitations.
A Common, Growing Need
Millions of coronary and peripheral interventions are performed each year, many in first-time patients.
Today's Standard Has Limits
Drug-eluting stents are effective but carry long-term risks associated with permanent implants.
Alternatives Fall Short
Drug-eluting balloons avoid implants but lack vessel support, markers, and protection against recoil or dissection.
There is a clear need for a solution that combines the strengths of DES and DEB while addressing their shortcomings.
Our Solution
Casper MRS provides temporary vessel support with radial strength comparable to drug-eluting stents, then fully resorbs within one year—leaving nothing behind to enable natural healing and prevent long-term complications like thrombosis.
Casper MRS marker
Structural Attributes
Magnesium alloy for complete bio-absorption
Resists arterial recoil during healing
Allows post-dilatation and multiple expansions
Supports dissections with interlocking multi-link design
Umirolimus Drug Platform
Abluminal coating (outside vessel only)
Highly lipophilic drug (10× more than Sirolimus)
Anti-inflammatory action with long drug retention
Proven in over 20M human implants
Thin Struts & Markers
Ultra-thin 90μm struts for easy delivery
Four dysprosium markers for visibility
Modified surface to enhance drug absorption
Interlocking struts for repeat inflations
Contact
For inquiries, you may use this form. It will open your email client — no information is stored on this site.
